Leveraging USPTO Delays To Maximize Patent Term

Before the USPTO was subject to a hiring freeze, it assumed it would onboard 400 new examiners between fiscal year 2025 and fiscal year 2026, and still predicted of unexamined patent applications. With a hiring freeze in place, the current backlog at nearly 838,000 unexamined patent applications, and the wait for initial examination already over 20 months, applicants can expect to increase. While these delays may not be ideal, applicants can leverage them to their advantage by maximizing patent term through patent term adjustment (PTA) awards.

USPTO Examination Delays Result in PTA Awards

By statute, the USPTO must award patent term adjustment when it fails to meet certain examination timeline metrics, including issuing a first Office Action within 14 months and taking no more than three years to grant a patent. from January 2025 show that barely 30% of patent applications are being examined within 14 months, and the number of patents taking more than three years to grant is at a two-year high of over 20%. Assuming patent application filings maintain their current level or (more likely) increase, more patents could be eligible for longer PTA awards.

Avoiding PTA Deductions for Applicant Delay

Not all USPTO delays result in PTA awards. The final PTA calculation subtracts any “applicant delay” from USPTO delay. Applicants seeking to maximize patent term should take care to minimize PTA deductions, including by:

Ensuring a compliant Sequence Listing is filed within eight months of the application filing date or national stage commencement date
Avoiding filing a preliminary amendment or other preliminary paper more than eight months after the filing date (or national stage commencement date) and less than one month before the mailing of an Office Action
Understanding how Information Disclosure Statement (IDS) rules differ from PTA rules and timing IDS submissions to minimize PTA deductions

Currently, U.S. national stage applications (based on PCT applications) experience much longer early-stage processing delays than directly filed U.S. applications (on the order of months to years). If this trend continues, opting to pursue a U.S. patent via the PCT/national stage route could be another approach to earn significant PTA.

Avoiding Terminal Disclaimers That Override PTA

Even if a patent is awarded significant PTA, entitlement to that extended term could be in jeopardy if a terminal disclaimer is filed over a patent with a shorter term. To avoid leaving PTA on the table, applicants should consider portfolio development strategies that minimize the need for terminal disclaimers, such as by:

Including multiple independent claims in an original application to trigger restriction requirements
Responding to restriction and election of species requirements without traverse to preserve the right to file divisional applications
Filing true divisional applications entitled to the protections of 35 U.S.C. 121 against obviousness-type double patenting (OTDP), and invoking the safe harbor of 35 U.S.C. 121 as a defense to OTDP
Appealing weak rejections instead of filing RCEs to earn PTA from favorable appeal decisions and avoid the PTA implications of RCEs
Minimizing voluntary continuation applications that can raise OTDP issues
Understanding the contours of recent Federal Circuit decisions such as Cellect and Allergan on the interplay between OTDP, terminal disclaimers, and PTA

While USPTO examination delays may present challenges for stakeholders building their patent portfolios, they also present opportunities to maximize value through longer patent terms. By pursuing strategies that minimize PTA deductions and preserve PTA awards, applicants can significantly extend the life of their patents, potentially creating additional opportunities to capitalize on their innovations. As USPTO examination delays continue to grow, effectively leveraging them to maximize patent term could provide a competitive edge in the market, especially in industries such as biotechnology and pharmaceuticals, where long-term patent protection can be important.

To learn more about patent term adjustment and how you can leverage USPTO delays to your advantage, reach out to your contact at �鶹��ý or any of the authors.

Disclaimer

This blog is made available by �鶹��ý (“�鶹��ý” or “the Firm”) for informational purposes only. It is not meant to convey the Firm’s legal position on behalf of any client, nor is it intended to convey specific legal advice. Any opinions expressed in this article do not necessarily reflect the views of �鶹��ý, its partners, or its clients. Accordingly, do not act upon this information without seeking counsel from a licensed attorney. This blog is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Communicating with �鶹��ý through this website by email, blog post, or otherwise, does not create an attorney-client relationship for any legal matter. Therefore, any communication or material you transmit to �鶹��ý through this blog, whether by email, blog post or any other manner, will not be treated as confidential or proprietary. The information on this blog is published “AS IS” and is not guaranteed to be complete, accurate, and or up-to-date. �鶹��ý makes no representations or warranties of any kind, express or implied, as to the operation or content of the site. �鶹��ý expressly disclaims all other guarantees, warranties, conditions and representations of any kind, either express or implied, whether arising under any statute, law, commercial use or otherwise, including implied warranties of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall �鶹��ý or any of its partners, officers, employees, agents or affiliates be liable, directly or indirectly, under any theory of law (contract, tort, negligence or otherwise), to you or anyone else, for any claims, losses or damages, direct, indirect special, incidental, punitive or consequential, resulting from or occasioned by the creation, use of or reliance on this site (including information and other content) or any third party websites or the information, resources or material accessed through any such websites. In some jurisdictions, the contents of this blog may be considered Attorney Advertising. If applicable, please note that prior results do not guarantee a similar outcome. Photographs are for dramatization purposes only and may include models. Likenesses do not necessarily imply current client, partnership or employee status.